Capecitabine
High-grade B-cell Lymphoma
Huiqiang HuangSmall moleculePhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
33 Active assets in the High-grade B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE OHSU Knight Cancer Institute | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
Cytosin-Arabinosid City of Hope Medical Center | Phase 3 | B |
Fludarabine Paolo Caimi, MD | Phase 2 | B |
View all 41 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →